Cargando…
非小细胞肺癌脑转移的靶向和免疫治疗
Brain metastasis, a common complication of non-small cell lung cancer (NSCLC) with an incidence rate of 30%-50%, significantly affects the patients' quality of life.The prognosis of patients of NSCLC with brain metastasis is extremely poor, the average median survival is only 1 m-2 m without tr...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5972989/ https://www.ncbi.nlm.nih.gov/pubmed/27561803 http://dx.doi.org/10.3779/j.issn.1009-3419.2016.08.08 |
| _version_ | 1783326516041482240 |
|---|---|
| collection | PubMed |
| description | Brain metastasis, a common complication of non-small cell lung cancer (NSCLC) with an incidence rate of 30%-50%, significantly affects the patients' quality of life.The prognosis of patients of NSCLC with brain metastasis is extremely poor, the average median survival is only 1 m-2 m without treatment.The targeted therapy based on lung cancer driven gene is a new treatment.Besides, the immunotherapy which can enhance the effect of anti-cancer by simulating the immune system is a new approach.The combination of targeted therapy and immunotherapy can greatly benefit patients in clinical work. |
| format | Online Article Text |
| id | pubmed-5972989 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2016 |
| publisher | 中国肺癌杂志编辑部 |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-59729892018-07-06 非小细胞肺癌脑转移的靶向和免疫治疗 Zhongguo Fei Ai Za Zhi 肺癌脑转移专题 Brain metastasis, a common complication of non-small cell lung cancer (NSCLC) with an incidence rate of 30%-50%, significantly affects the patients' quality of life.The prognosis of patients of NSCLC with brain metastasis is extremely poor, the average median survival is only 1 m-2 m without treatment.The targeted therapy based on lung cancer driven gene is a new treatment.Besides, the immunotherapy which can enhance the effect of anti-cancer by simulating the immune system is a new approach.The combination of targeted therapy and immunotherapy can greatly benefit patients in clinical work. 中国肺癌杂志编辑部 2016-08-20 /pmc/articles/PMC5972989/ /pubmed/27561803 http://dx.doi.org/10.3779/j.issn.1009-3419.2016.08.08 Text en 版权所有©《中国肺癌杂志》编辑部2016 https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/ |
| spellingShingle | 肺癌脑转移专题 非小细胞肺癌脑转移的靶向和免疫治疗 |
| title | 非小细胞肺癌脑转移的靶向和免疫治疗 |
| title_full | 非小细胞肺癌脑转移的靶向和免疫治疗 |
| title_fullStr | 非小细胞肺癌脑转移的靶向和免疫治疗 |
| title_full_unstemmed | 非小细胞肺癌脑转移的靶向和免疫治疗 |
| title_short | 非小细胞肺癌脑转移的靶向和免疫治疗 |
| title_sort | 非小细胞肺癌脑转移的靶向和免疫治疗 |
| topic | 肺癌脑转移专题 |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5972989/ https://www.ncbi.nlm.nih.gov/pubmed/27561803 http://dx.doi.org/10.3779/j.issn.1009-3419.2016.08.08 |
| work_keys_str_mv | AT fēixiǎoxìbāofèiáinǎozhuǎnyídebǎxiànghémiǎnyìzhìliáo AT fēixiǎoxìbāofèiáinǎozhuǎnyídebǎxiànghémiǎnyìzhìliáo AT fēixiǎoxìbāofèiáinǎozhuǎnyídebǎxiànghémiǎnyìzhìliáo |